This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Centre National De La Recherche Scientifique. Active years: 2000.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2000
Title: David Ojcius: Innovator in Immunology
Introduction
David Ojcius is a prominent inventor based in Vincennes, France. He has made significant contributions to the field of immunology, particularly through his innovative patent related to major histocompatibility complex (MHC) determinants. His work has implications for the treatment and immunization of various diseases.
Latest Patents
Ojcius holds a patent for an altered major histocompatibility complex (MHC) determinant and methods. This invention involves an altered MHC class I determinant that comprises .alpha..sub.1, .alpha..sub.2, .alpha..sub.3, and .beta..sub.2 -microglobulin (.beta..sub.2 m) polypeptide domains. These domains are encoded by a mammalian MHC class I locus, where the .alpha..sub.3 domain is covalently linked to the .beta..sub.2 m domain. Additionally, the altered MHC class II determinant includes .alpha..sub.1, .alpha..sub.2, .beta..sub.1, and .beta..sub.2 polypeptide domains, which are also covalently linked to form a specific sequence. The altered MHC determinants can be associated with an antigen to elicit an immune response, making this invention valuable for immunization or treatment of diseases such as AIDS, multiple sclerosis, lupus erythematosus, toxic shock, or snake bites. He has 1 patent to his name.
Career Highlights
Throughout his career, David Ojcius has worked with esteemed institutions such as the Institut Pasteur and the Centre National de la Recherche Scientifique. He has also been associated with Yissum Research Development Company of the Hebrew University of Jerusalem Ltd., where he has contributed to various research initiatives.
Collaborations
Ojcius has collaborated with notable colleagues, including Jean-Pierre Abastado and Estelle Mottez. Their joint efforts have further advanced the field of immunology and contributed to the development of innovative solutions.
Conclusion
David Ojcius is a distinguished inventor whose work in immunology has the potential to impact the treatment of several diseases. His innovative patent on altered MHC determinants showcases his commitment to advancing medical science.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile